Introduction
Adrenocortical carcinoma (ACC) is a rare malignancy with an estimated worldwide annual incidence of 1 to 2 per million. 1 It is responsible for only approximately 0.2% of all cancer deaths in the United States annually, and it is the second most aggressive endocrine malignancy following anaplastic thyroid cancer. 2 ACC carries a poor prognosis, with an expected 5-year survival of 13% in patients with stage IV disease. 3 Surgery is the mainstay treatment in localized ACC and creates the best hope for prolonged survival and potential cure. However, 60% of patients who present with localized disease experience recurrence that often requires systemic therapy. 4 Herein, we present a case report of a recurrent and metastatic ACC with a rare discoid domain receptor-2 (DDR2) mutation with an ongoing long-term survival of more than 11 years achieved with surgery, chemotherapy, and mitotane retreatments. To date, only 8 case reports, 1 small case series of 6 patients, and 12 patients from multicenter retrospective analysis in the literature have reported on patients with ACC who have achieved long-term survival of more than 10 years. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The 5-year and 10-year survival of patients with metastatic disease reported by Tran et al 14 from the multicenter retrospective analysis was 27% and 7%, respectively.
Case Report
A 57-year old man presented with left flank pain on February 2006. Computed tomography (CT) scan of the abdomen revealed a 4.5-cm left adrenal mass. He underwent a fine-needle biopsy with a cytological finding suggestive of a malignant tumor. A complete metabolic evaluation for pheochromocytoma was negative. Subsequently, he elected for laparoscopic left adrenalectomy. Histological finding confirmed an adrenal cortical carcinoma with negative margins, no capsule involvement, low to moderate mitotic activity, and the presence of vascular invasion. Postsurgical CT staging examination showed no evidence of metastatic disease and the diagnosis of a low-risk stage I ACC was made. The patient was enrolled into a routine follow-up with regular CT scans, and clinical and laboratory examinations for the first 2 years postoperatively. He was free of recurrence during these visits, and then he was lost to follow-up for 4 years until November 2012 when he presented with symptoms of gross hematuria and back pain.
Radiologic studies at that time revealed recurrent disease with a left adrenal mass abutting the left kidney and spleen, left retroperitoneal mass, and left paraspinal soft tissue mass ( Figure 1A ). In January 2013, He underwent a retroperitoneal lymph node dissection and left partial nephrectomy with pathological diagnosis of 5.2-cm recurrent left adrenal cortical carcinoma invading left
Clinical Practice Points Clinical Practice Points
Adrenal cortical carcinoma (ACC) is a rare malignancy with poor prognosis. The high rate of recurrence in this disease emphasizes the necessity for careful clinical and radiographic follow-up for timely diagnosis of a recurrence. Patients with recurrent or metastatic disease should undergo repeat surgery, if the tumor is potentially resectable, because surgery may significantly prolong median survival.
In this brief report, a 57-year-old man with recurrent and metastatic ACC achieved long-term survival of 11 years with surgery, chemotherapy, and mitotane. Whole genome sequencing of tumors can shed light on possible therapeutically relevant events that might help inform treatment recommendations for advanced cancers. Figure 1B) . A liver biopsy confirmed metastatic ACC. Subsequently, the patient was treated with 6 cycles of etoposide, doxorubicin, and carboplatin (EDP), with concomitant oral mitotane (the dose titrated according to serum mitotane levels), 15 until July 2014 when the CT scan revealed no evidence of progression or new metastases. He progressed with numerous bilateral small pulmonary nodules on CT images in January 2015, but the liver remained disease free ( Figure 1C) . As a result, he was reintroduced to a daily single-agent treatment with mitotane, which he continues to take until the present time.
Whole genome sequencing from the relapsed resected tumor mass, was performed. The tumor was largely devoid of mutations, copy number alterations, or translocations. However, a discoid domain receptor-2 (DDR2) missense mutation was discovered. The tumor sample's exonic mutation rate was estimated to be 0.5 mutations per megabase.
The patient is still alive with radiology studies showing stable pulmonary nodules and no evidence of progression on 2.5 g daily mitotane alone. His long-term survival has reached more than 11 years at the last follow-up in April 2017.
Discussion ACC is a rare endocrine malignancy. A complete resection of the primary tumor is the only potentially curative treatment; however, even in patients who undergo radical adrenalectomy for a stage I disease, recurrence is common. 4 A prognosis of metastatic disease is dismal. The treatment of recurrence has been predominantly based on chemotherapy and mitotane, although some patients may benefit from surgical resection of a disease that is anatomically confined. The overall survival of EDP plus mitotane is approximately 14 months. 15 Mitotane is currently a cornerstone in the management of cortisol secreting ACC inducing adrenal cortex necrosis, mitochondrial membrane impairment, and irreversible binding to CYP proteins, including CYP11A1, CYP11B1, CYP11B2, and 3b-hydroxysteroiddehydrogenase. 16, 17 However, the degree of response to mitotane is variable among patients because of the complexity of its mechanisms of action, pharmacokinetics, and tolerability. The course of this patient was remarkable because he achieved an ongoing long-term survival with metastatic ACC after treatment with mitotane and chemotherapy. The finding of the genome largely devoid of mutations with the exception of single DDR2 mutation in this patient could be a contributing factor to his excellent survival and high sensitivity to mitotane. In contrast to our patient, ACC is generally known to have a high mutational burden. 18, 19 DDR2 is a receptor tyrosine kinase that interacts with collagen and plays a role in cell adhesion and proliferation. 20 DDR2 was found to be mutated in approximately 4% of patients with lung squamous cell carcinoma, 21 lung adenocarcinoma, and gastric and breast cancer, but not in ACC. 18, 19 Recent report from a preclinical cell-line and tissue-based model suggests that somatic mutations in DDR2 are responsive to dasatinib (a DDR2 receptor tyrosine kinase inhibitor). 22 Early case reports also have also reported sensitivity to dasatinib in squamous cell carcinoma of the lung. 23 Based on the results from whole genome sequencing of the patient's tumor, we hypothesize that treatment with dasatinib could be a meaningful approach in case of further progression of the disease. A long-time Survival in a Patient with Metastatic DDR2 Positive ACC Whole genome sequencing can identify tumor drivers and potential actionable mutations, generally brings detailed information on tumor heterogeneity, and guides clinicians in decision making for treatment recommendations in advanced cancers. We suggest whole genome sequencing in selected patients who have previously failed standard treatments and/or in patients with unexpected biological behavior of the ACC.
Conclusion
This case report demonstrates an exceptionally rare long-term survival of a patient with metastatic ACC. His survival exceeding 11 years was achieved by chemotherapy, surgery, and mitotane retreatments. A rare DDR2 mutation was discovered that could be illustrative of a different biological behavior of ACC in our patient.
